-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The IO-CT combination has become the standard of care for patients with aNSCLC with low or moderate programmed death ligand 1 (PD-L1) expression (<50%) and is also an option for patients with high PDL1 expression (≥50%.
This study was a retrospective international study including patients who progressed under a first-line IO-CT regime.
This study enrolled 125 patient.
In the IO-CT major resistant population (n=21), mOS-L2 was not achieved in the platinum-containing chemotherapy group, compared with 8, 2, and 7 months in the T-mono, T-AA, and other chemotherapy groups, respectivel.
The results show that for aNSCLC patients, second-line therapy after IO-CT can provide a certain curative effec.
Original source:
OA006-Second Line Treatment Outcomes After Progression on Immunotherapy Plus Chemotherapy (IO-CT) In Advanced Non-small Cell Lung Cancer (aNSCLC)